SubB2M came from the 'merger' with Sienna which licensed the IP back in April 2020 from the University of Adelaide and Griffith University.
SubB2M does NOT make other cancer diagnostics redundant.
It is a Pan-Cancer probe which can detect cancer at 100% accuracy, but doesn't tell you what type of cancer you have or where the cancer is.
For that you need cancer specific tests like BARD1 and these products will therefore complement each other.
In fact, the really exciting aspect of SubB2M is that it can be used to improve the accuracy of other cancer diagnostics. (RHY should be talking to BD1)
SubB2M will also be a relatively inexpensive ELISA test, meaning it's ideal for annual government sponsored screening tests.
Laughable BOT & Weak Hand BS, page-15
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
57.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $63.40M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 37420 | 56.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 57.5¢ | 12112 | 1 |
View Market Depth
| Last trade - 11.52am 15/08/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |
Day chart unavailable